Resources Publications, Posters, Webinars, Videos and Brochures

Brochure Immunoscore® in Localized CC (CLIA US version)

For Healthcare Professionals (CLIA US version)

Brochure Immunoscore® in Localized CC (CE/IVD version)

For Healthcare Professionals (CE/IVD version)

Brochure IVD Development

HalioDx provides flexible services for IVD assay development for companies in the diagnostics and pharma industries, for technology providers and for clinical labs.

Brochure Immunoscore® in Localized Colon Cancer

For Patients & Caregivers (English)

Dr Mellor, Malaysia, explains why and how he is using immmunoscore in Stage III colon cancer patients

Professor Yoshino, KOL in Asia region, talk about Immunoscore

Leaflet Immunoscore® in Stage II Colon Cancer

For Healthcare Professionals (English version)

Leaflet Immunoscore® in High-risk Stage II Colon Cancer

For Healthcare Professionals (English version)

Leaflet Immunoscore® in Stage III Colon Cancer

For Healthcare Professionals (Ennglish version)

ASCO Quality Care Symposium on October 9-10, 2020

Impact of Immune Assessment with Immunoscore® on Patterns of Care In Stage II Colon Cancer

Dr Tony Dhillon (UK) presenting Immunoscore at the Digestive Cancers Europe Scientific Update: Role of the Immune Response in Early Stage Colorectal Cancers

Testimonial: Dr Su Pin Choo (Curie Oncology, Singapore) on the utility of Immunoscore in early stage Colon Cancer

Managing colorectal cancer patients in the COVID-19 era with Drs Benjamin Weinberg (USA), Matías Chacón and Juan Manuel O’Connor (both Argentina)

Mlecnik B Bifulco C, Bindea G, et al.

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer

J Clin Oncol.

2’ to learn more Series: Jacques Fieschi PhD, VP, R&D, presents the R&D department and its technologies, with a focus on Brightplex®

El Sissy C, Kirilovsky A, Van den Eynde M et al.

A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy

Clin Cancer Res

F Pages, J Taieb, P Laurent-Puig, and J Galon

The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions

OncoImmunology

Bruni D, K Angell H and Galon J

The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

Nature Reviews Cancer

Immunoscore® highlights at ESMO GI. Presentations of Dr Le Bagousse and Jérôme Galon, PhD

A Lanzi,F.A Sinicrope, A.B Benson, and J Galon

The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions

OncoImmunology

A Lanzi,F Pages, C Lagorce-Pages, and J Galon

The consensus immunoscore: toward a new classification of colorectal cancer

OncoImmunology

Unravelling the mystery of cancer-associated fibroblast (CAF) populations in the tumor microenvironment by a fully automated sequential chromogenic multiplex assay

AACR2020 Abstract # 5970

O’Connor JM, Esteso F & Chacón M

Official French SARS-CoV-2 guidelines for cancer patients, a triage solution with precision medicine

Future Medicine

Webinar: Exploring Changes of Myeloid Cells with Chromogenic Multiplex IHC in Advanced Liver Cancer| Prof. Nagy Habibi & Jacques Fieschi, PhD

Testimonial: Dr Juan Manuel O’Connor (Instituto Alexander Fleming in Buenos Aires, Argentina) on the use of Immunoscore in routine practice in managing early Colon Cancer

Factsheet Immunoscore® & COVID-19 Colon Cancer Guidelines

Poster presented at ASCO20 Virtual Scientific meeting#ASCO20

Immunoscore is the most powerful parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients Abstract 4105

Marliot F, Chen X, Kirilovsky A et al.

Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer

BMJ

Expert Opinion: The Role of Microbiota and its Impact on the Tumor Microenvironment in Colorectal Cancer | Dr Benjamin A. Weinberg, MD, Oncologist in Georgetown, Washington DC

2’ to learn more Series: Who are HalioDx solutions designed for? | Vincent Fert, President & CEO

2’ to learn more Series: HalioDx presentation and the company's activities during COVID 19 Pandemic | Vincent Fert, President & CEO

Webinar: Capturing the Complexity of the Tumor Microenvironment | Jérôme Galon, PhD & Jacques Fieschi, PhD

Expert Opinion: Immunity and cancer | Dr Angela Alistar, MD, Oncologist in Morristown, NJ

Unravelling the mystery of cancer-associated fibroblasts (CAFs) populations in the tumor microenvironment by fully automated sequential chromogenic multiplex assay (AACR 2020)

Sinicrope F, Shi Q, Hermitte F et al.

Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer

JNCI Cancer Spectrum

Pages F, Andre T, Taieb J et al.

Prognostic and Predictive Value of the Immunoscore in Stage III Colon Cancer Patients Treated With Oxaliplatin in the Prospective IDEA France PRODIGE-GERCOR Cohort Study

Annals of Oncology

Blair H

Immunoscore®: A Diagnostic Assay for Clinical Management of Colon Cancer

Molecular Diagnosis & Therapy volume

Franck Pagès, MD, PhD, on Selecting Patients With Advanced Colon Cancer for Treatment

Poster presented at Gastro Intestinal Symposium #GI20

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (3 vs 6 months) in the prospective IDEA France cohort study

Pagès F, Kirilovsky A, Mlecnik B et al.

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

Journal of Clinical Oncology

Poster presented at SITC 2019

Immunogram to decipher PD1/L1 ICI resistance: a proof of concept in advanced Non-small cell lung cancer patients of the PIONeeR Project.

Brochure Immunoscore® in Localized Colon Cancer - SPANISH

For Patients & Caregivers (Spanish)

Webinar: Evaluating Biomarkers During Clinical Trials for Immunotherapies. A Case Study on the Pioneer Project

Unveiling Tumor-Associated Macrophages (TAMs) heterogeneity and plasticity by a fully automated sequential chromogenic multiplex assay (SITC 2019)

Cancer Immunogram: combining multi-parameter approach and machine learning to capture the complexity of tumor immune contexture. (SITC 2019)

Poster presented at ESMO 2019 by Transgene

In the Phase Ib/II trial of TG4001, HalioDx Immunoscore®, Immunosign® and others clinical research service have been performed to assess Immune contexture of patients.

Poster presented at SITC 2019

Tumor Infiltrating Lymphocytes (TILs) in triple-negative breast cancer: High Immunoscore is associated with pathological CR in patients receiving neoadjuvant chemotherapy.

Poster presented at ESMO 2019

High Immunoscore® is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced Head and Neck cancer patients.

Webinar Immunoscore®: IDEA France study results in Stage III Colon Cancer - Sept. 19, 2019 | Franck Pagès, Eric Van Cutsem

Webinar Biomarker Evaluation for CAR T-Cell Therapy: Impact on Drug Development

Angell HK, Bruni D, Barrett JC et al.

The Immunoscore: Colon Cancer and Beyond.

Clin Cancer Res.

Poster presented at ESMO GI 2019

Significant differences in outcome between Immunoscore categories in stage I colon cancer patients

Mascaux C, Angelova M, Vasaturo A et al.

Immune evasion before tumour invasion in early lung squamous carcinogenesis.

Nature

HalioDX is part of the COLOSSUS project by performing Immunoscore and help stratification of difficult to treat mCRC patients with a final objective to Improve their management and treatment

Extract of an interview by Cancer.fr of Professor Thierry André, on Immunoscore® in the IDEA France study (in French)

Webinar on Brightplex®: Combining the power of multiplexing & the ease of chromogenic IHC to assess complex immune phenotype

Jérôme Galon, winner for the European Inventor Award 2019 for Immunoscore®

Poster presented at ASCO 2019

Validation of the Immunoscore Prognostic Value in Stage III Colon Cancer Patients treated with Oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

Discover HalioDx - Reportage by Grand Luminy Technopole - April 2017

Galon J & Bruni D

Tumor Immunology and Tumor Evolution: Intertwined Histories

Immunity

Pages F, Andre T, Taieb J et al.

Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR)

Journal of Clinical Oncology

Immunogram Clinical Seminar (Atlanta, April 2019) | Jérôme Galon, PhD

Immunogram Clinical Seminar (Atlanta, April 2019) | Jacques Fieschi, PhD

Validation of Brightplex®: a multiplex IHC solution for immune cell phenotyping of the tumor microenvironment (AACR 2019)

Dr. Fakih Discusses the Utility of Immunoscore® in CRC

Poster presented at AACR 2019

Combining multimodal biomarkers as an immunogram to guide immunotherapy use: A Proof of Concept

Poster presented at AACR 2019 by Lytix biopharma

A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefits in patients with advanced sarcoma

Poster presented at AACR 2019 by Lytix biopharma

A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma

Immunoscore® Webinar New data in Stage II Colon Cancer - March 21, 2019 | Jêrome Galon, PhD

Zeitoun G, Sissy CE, Kirilovsky A et al.

The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.

Chirurgia (Bucur).

Brochure Clinical Research

HalioDx Biopharma Services

Galon J & Bruni D

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.

Nat Rev Drug Discov.

Discover how Immunoscore® is predicting the risk of relapse in localized colon cancer in a short video

Poster presented at Gastrointestinal Cancers Symposium 2019

Immunoscore clinical utility to identify good prognostic Colon Cancer Stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided

Poster presented at ESMO ASIA 2018

UCGI 34 - PROSCORE: A prospective study assessing whether Immunoscore® test impacts the choice of adjuvant chemotherapy, in a multidisciplinary meeting, for treating non-metastatic colon cancer patients after curative-intent surgery

Poster presented at ESMO IO 2018

MSI status plus Immunoscore to select metastatic colorectal cancer patients for immunotherapies

Myeloid-derived suppressor cells (MDSC) assessment using an automated sequential chromogenic multiplex assay (Brightplex®) (SITC 2018)

Poster presented at ESMO ASIA 2018

Immunoscore feasibility study in routine postsurgical pathologic review for early‐stage colon cancer (CC) cases risk‐assessment

Angelova M, Mlecnik B, Vasaturo A et al.

Evolution of Metastases in Space and Time under Immune Selection.

Cell

Poster presented at the CRI-CIMT-EATI-AACR 2018

T cell exhaustion assessment using an automated sequential chromogenic multiplex assay (Brightplex®)

Webinar on “Clinical utility of Immunoscore® in colon cancer” with Marc Van Den Eynde, MD, PhD | October 17, 2017

Dr Jerome Galon on the Prognostic Value of Immunoscore, Onclive - ASCO 2016

Immunoscore® Colon Symposium - June 1, 2018, Chicago | Discussion on clinical cases

Immunoscore® Colon Symposium - June 1, 2018, Chicago | Jérôme Galon, PhD

Immunoscore® Colon Symposium - June 1, 2018, Chicago | Stanley Hamilton, MD

Poster presented at ASCO 2018 by Lytix biopharma

A Phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors

Pagès F, Mlecnik B, Marliot F et al.

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Lancet

Poster presented at AACR 2018

Multi-centric PD-L1 and CD8 IHC assessment in NSCLC using IMMUNOSCORE® IC previously Halioseek®) CE-IVD assay

Poster presented at ASCO GI 2018

Immunoscore provides prognostic information in low (T3N1) and high (T4 or N2) risk subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)

Sinicrope F, Shi Q, Hermitte F et al.

Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

J Clin Oncol.

Mlecnik B, Van den Eynde M, Bindea G et al.

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.

J Natl Cancer Inst.

Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G

The immune contexture in cancer prognosis and treatment.

Nat Rev Clin Oncol.

Poster presented at SITC 2017 by Lytix biopharma

LTX-315, a first in class oncolytic peptide, reshapes the tumor microenvironment in the patients with advanced metastatic tumors: Results from an ongoing study

Poster presented at SITC 2017

Immunoscore IC (previously Halioseek® PD‐L1/CD8), a dual CD8 and PD‐L1 IVD assay to improve NSCLC patients stratification

Poster presented at NSH 2017

A multiplex immunohistochemistry assay for immune cells profiling on whole FFPE tumor tissue sections

Poster presented at ASCO 2017

Prognostic utility of immune markers and validation of Immunoscore® in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)]

Poster presented at ASCO 2017 by Kite Pharma

Poster presented at ASCO 2017 by Lytix biopharma

LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment inducing a local and systemic effect in metastatic tumors: Results from an ongoing study

Sinicrope F, Shi Q, Hermitte F et al.

Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).

J Clin Oncol.

Galon J, Mlecnik B, Marliot F et al.

Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.

J Clin Oncol.

Poster presented at AACR 2017

A new standardized CD8 and PD-L1 dual assay

Poster presented at SITC 2016

Immunoscore® analytical performance

Hermitte F

Biomarkers immune monitoring technology primer: Immunoscore® Colon.

Journal for ImmunoTherapy of Cancer

Kirilovsky A, Marliot F, El Sissy C et al.

Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.

Int Immunol.

Mlecnik B, Bindea G, Angell HK et al.

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

Immunity

Mlecnik B, Bindea G, Kirilovsky A et al.

The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.

Sci Transl Med.

Berghoff AS, Fuchs E, Ricken G et al.

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Oncoimmunology

Bindea G, Mlecnik B, Tosolini M et al.

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

Immunity

Galon J, Angell HK, Bedognetti D, Marincola FM

The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.

Immunity

Fridman WH, Pagès F, Sautès-Fridman C, Galon J.

The immune contexture in human tumours: impact on clinical outcome.

Nat Rev Cancer.

Mlecnik B, Tosolini M, Kirilovsky A et al.

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

Journal of Clinical Oncology

Galon J, Costes A, Sanchez-Cabo F et al.

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Science